NCT05352321View on ClinicalTrials.gov

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Gemcitabine

for induction chemotherapy

DRUG

Cisplatin

for induction and concurrent chemotherapy

RADIATION

regular intensity-modulated radiotherapy

in active comparator arm

PROCEDURE

surgery

in experimental arm

RADIATION

Target-reduction intensity-modulated radiotherapy

in experimental arm

Trial Locations (2)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Unknown

RECRUITING

Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER